Business Wire

Western Union and the Western Union Foundation Expand Funding for Global COVID-19 Relief

Share

The Western Union Foundation has announced a commitment of an additional USD $300,000 in the global fight against COVID-19, making the combined funds pledged by Western Union and the Western Union Foundation USD $800,000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200427005795/en/

The Western Union Foundation giving priorities have been updated to include strengthening healthcare systems around the globe that are serving some of the world’s most vulnerable populations, including refugees and migrants. Additionally, the Foundation will continue to support local and global nonprofit organizations providing access to essential services including hunger relief, medical training, education, supplies and equipment for frontline healthcare workers.

Major global non-governmental organizations to benefit from the giving include the UN Foundation COVID-19 Solidarity Response Fund, Give2Asia, International Medical Corps and in the U.S. the Chicago Community COVID-19 Response Fund.

In February, Western Union and the Western Union Foundation announced a one million dollar global matching challenge, with a commitment to match up to USD $500,000 in the fight against COVID-19 making personal, corporate, employee and Agent donations go further in this fight. The deadline for the global matching challenge has been extended through May 15.

“Working with Western Union Agents, customers and employees to make their dollars go further demonstrates the power of collaboration in supporting displaced and marginalized communities around the globe during the COVID-19 pandemic,” said Elizabeth Roscoe, Global Head, Corporate Brand and Purpose, and Executive Director, Western Union Foundation. “We are humbled and eternally grateful for the commitment of all frontline workers who continue to show up each day to deliver essential services in these unprecedented times. They are the heroes of our time.”

The Western Union Foundation is focused on supporting marginalized and displaced communities, including migrants and refugees. These vulnerable populations are less likely to have access to the information, medical assistance and supplies needed to combat this virus. It is critical we work with partners that are supporting these individuals so the coronavirus can be both contained and treated, as well as respond to acute community needs like food insecurity brought on as a result of COVID-19.

Western Union and the Western Union Foundation are investing USD $800,000 – plus the proceeds raised from Agents, customers and employees during the global matching challenge – in nonprofits around the world that are responding to COVID-19 related issues. Outlined below are a few recent campaign highlights:

  • Tony’s Charitable Foundation: The charitable arm of Tony’s Fresh Market, a Western Union Agent in Chicago, donated USD $50,000 to the global matching challenge fund. Their gift was matched by the Western Union Foundation for a total of $100,000 being directed to the Chicago Community COVID-19 Response Fund for essential services such as emergency food and healthcare supplies.
  • Give2Asia: The Western Union Foundation committed to fund local response efforts during the coronavirus outbreak across the Asia-Pacific region to deliver critical medical supplies including hundreds of thousands of masks to protect health workers and at-risk populations, tens of thousands of liters of disinfectant for hospitals and meals for medical staff and patients.
  • International Medical Corps: The Western Union Foundation committed to fund COVID-19 training for healthcare workers in the Philippines for infection prevention, control, and to prepare for a surge in cases; personal protective equipment, including gloves, goggles, gowns and hundreds of thousands of masks to the Manila Health Department for frontline healthcare workers safe; and set up of screening and triage tents at a hospital in Manila.
  • UN Foundation COVID-19 Solidarity Response Fund: A commitment of $100,000 to support the World Health Organization’s work to track and understand the spread of the virus, ensure patients get the care they need and frontline workers get essential supplies and information, and to accelerate research and development of a vaccine and treatments for all who need them.

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of December 31, 2019, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.

About the Western Union Foundation

The Western Union Foundation believes that education is the surest pathway to economic opportunity. After nearly 20 years of impact, we are continuing to deliver against our mission with our Opportunity Beyond Borders commitment, with a focus on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. The Foundation also provides funding to communities in crisis through disaster relief and other humanitarian efforts, a key reason for forced migration. To date, more than $125 million has been given to fund projects and scholarships in 174 countries across the globe. The Western Union Foundation is a separate charitable corporation that is tax-exempt under 501(c)(3) of the US Internal Revenue Code, and receives support from The Western Union Company, its employees, agents and business partners. Contributions to the Foundation are tax-deductible for US income tax purposes. To learn more, visit wu.com/foundation or follow us on Twitter @TheWUFoundation.

WU-G

Contact information

Media Contacts
Margaret Fogarty, Western Union
margaret.fogarty@wu.com 720-551-3393

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CESTPress release

Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 03:00:00 CESTPress release

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom